Adults patients having non severe HLH research hub

HLH-JAK - Treatment of non severe Hemophagocytosis Lymphohistiocytosis with ITACITINIB a Phase II prospective trial

This study is testing a new medicine called Itacitinib for adults with a non-severe form of a rare immune condition called HLH. Researchers want to see if it improves symptoms within 15 days, helping to calm down the overactive immune system.